Eli Lilly (LLY) Stock: Foundayo Outpaces Novo’s Ozempic in Latest Diabetes Data

Eli Lilly (LLY) releases data showing Foundayo beats Novo's Ozempic pill and Zepbound outperforms Wegovy HD in weight loss and diabetes management.

The post Eli Lilly (LLY) Stock: Foundayo Outpaces Novo’s Ozempic in Latest Diabetes Data appeared first on Blockonomi.